Abcellera Biologics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 15, 2022, details the results of Abcellera Biologics Inc.'s Annual Meeting of Shareholders. The meeting was held on June 15, 2022, with a record date of April 18, 2022. At the record date, there were 284,525,930 common shares outstanding and entitled to vote.
Key Financial Metrics
This filing is a corporate governance report regarding shareholder voting outcomes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
Shareholders voted on four proposals, all of which were approved:
- Proposal 1 (Director Election): Carl G. Hansen, Ph.D., and Michael Hayden, MBCHB (M.D.), Ph.D., were elected as Class II directors for a three-year term.
- Proposal 2 (Auditor Ratification): Shareholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Proposal 3 (Say on Pay): Shareholders approved the compensation of named executive officers on a non-binding advisory basis.
- Proposal 4 (Say on Pay Frequency): Shareholders approved a frequency of one year for future advisory votes on executive compensation.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of contingencies. It strictly reports the vote tallies for the Annual Meeting.
Investor Verification Checklist
- Verify the election of Carl G. Hansen and Michael Hayden as Class II directors serving until 2025.
- Confirm the ratification of KPMG LLP as the independent auditor for fiscal year 2022.
- Note the shareholder preference for annual Say on Pay votes (Proposal 4).
- Review the Definitive Proxy Statement filed on April 28, 2022, for detailed background on the proposals.